Rafarma Pharmaceuticals (RAFA) Stock Price & Analysis
RAFA Stock Chart & Stats
- Day’s Range
- $0.02 - $0.02
- 52-Week Range
- $0.00 - $0.09
- Previous Close
- $0.02
- Volume
- 6,800
- Average Volume (3M)
- 13.16K
- Market Cap
- $1.45M
- Enterprise Value
- $4.31T
- Total Cash (Recent Filing)
- $60.00K
- Total Debt (Recent Filing)
- $22.00K
- Price to Earnings (P/E)
- 7.4
- Beta
- 0.64
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
RAFA FAQ
What was Rafarma Pharmaceuticals’s price range in the past 12 months?
What is Rafarma Pharmaceuticals’s market cap?
When is Rafarma Pharmaceuticals’s upcoming earnings report date?
Is Rafarma Pharmaceuticals overvalued?
Does Rafarma Pharmaceuticals pay dividends?
What is Rafarma Pharmaceuticals’s EPS estimate?
How many shares outstanding does Rafarma Pharmaceuticals have?
Which hedge fund is a major shareholder of Rafarma Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Rafarma Pharmaceuticals
Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that manufactures and distributes a range of medicinal products, including generic antibiotics and specialized drugs, within the Russian market. Its product portfolio encompasses anti-cancer medications, cephalosporin-derived compounds, and non-beta-lactam antibiotics. These are available in various formats such as injectable solutions, ampoules, pediatric suspensions, oral tablets, and capsules. Additionally, Rafarma develops and supplies treatments for injuries, ocular inflammatory conditions, and immunological ailments. In a collaborative effort with PlantEXT Ltd., the company is involved in the research and production of pioneering medical cannabis suppositories, specifically designed for individuals afflicted with inflammatory bowel disease. Originally incorporated as Johnston Acquisition Corp., the firm adopted its current name, Rafarma Pharmaceuticals, Inc., in October 2012. While headquartered in Sandy, Utah, its primary manufacturing and distribution operations are situated in Russia. Since October 19, 2020, Rafarma Pharmaceuticals, Inc. has functioned as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Sergey Brusnitsin
- Employees
- 700
- Website
- www.rafarma.com
- Address
- 49 West 9000 South, Sandy, UT, 84070, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 5 | 8 |
| Technical Analysis | 2 | 5 | 2 |
| Moving Averages | 6 | 0 | 6 |
